Structural basis of lenalidomide-induced CK1α degradation by the CRL4 CRBN ubiquitin ligase

Nature

Volumn 532, Issue 7597, 2016, Pages 127-130

  Petzold, Georg ^a,b   Fischer, Eric S ^a,b,c,d   Thomä, Nicolas H ^a,b  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; LENALIDOMIDE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; PROTEIN BINDING; THALIDOMIDE;

DEGRADATION; DISEASE TREATMENT; DRUG; DRUG DEVELOPMENT; ENZYME; PROTEIN; SUBSTRATE;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME BINDING; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; METABOLISM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CASEIN KINASE IALPHA; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; IKAROS TRANSCRIPTION FACTOR; MODELS, MOLECULAR; PROTEIN BINDING; PROTEOLYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THALIDOMIDE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84963542597     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16979     Document Type: Article

References (41)

1. Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999)
2. Bartlett, J. B., Dredge, K. & Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Rev. Cancer 4, 314-322 (2004)
3. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010)
4. Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49-53 (2014)
5. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014)
6. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science 343, 305-309 (2014)
7. Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br. J. Haematol. 164, 811-821 (2014)
8. Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183-188 (2015)
9. List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549-557 (2005)
10. Sekeres, M. A. & List, A. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? Curr. Hematol. Rep. 4, 182-185 (2005)
11. Schneider, R. K. et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509-520 (2014)
12. Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Struct. Mol. Biol. 21, 803-809 (2014)
13. Kornev, A. P., Haste, N. M., Taylor, S. S. & Eyck, L. F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad. Sci. USA 103, 17783-17788 (2006)
14. Schjerven, H. et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nature Immunol. 14, 1073-1083 (2013)
15. Zhou, S. et al. Transport of thalidomide by the human intestinal caco-2 monolayers. Eur. J. Drug Metab. Pharmacokinet. 30, 49-61 (2005)
16. Hofmeister, C. C. et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J. Clin. Oncol. 29, 3427-3434 (2011)
17. Krenn, M., Gamcsik, M. P., Vogelsang, G. B., Colvin, O. M. & Leong, K. W. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-beta-cyclodextrin. J. Pharm. Sci. 81, 685-689 (1992)
18. Roche, S. et al. Development, validation and application of a sensitive LC-MS/ MS method for the quantification of thalidomide in human serum, cells and cell culture medium. J. Chromatogr. B 902, 16-26 (2012)
19. Fischer, E. S. et al. The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147, 1024-1039 (2011)
20. Angers, S. et al. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590-593 (2006)
21. Duda, D. M. et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134, 995-1006 (2008)
22. Mahon, C., Krogan, N. J., Craik, C. S. & Pick, E. Cullin E3 ligases and their rewiring by viral factors. Biomolecules 4, 897-930 (2014)
23. Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015)
24. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015)
25. Milroy, L. G., Grossmann, T. N., Hennig, S., Brunsveld, L. & Ottmann, C. Modulators of protein-protein interactions. Chem. Rev. 114, 4695-4748 (2014)
26. Tan, X. et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-645 (2007)
27. Griffith, J. P. et al. X-ray structure of calcineurin inhibited by the immunophilinimmunosuppressant FKBP12-FK506 complex. Cell 82, 507-522 (1995)
28. Hartmann, M. D. et al. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J. Struct. Biol. 188, 225-232 (2014)
29. Abdulrahman, W. et al. A set of baculovirus transfer vectors for screening of affinity tags and parallel expression strategies. Anal. Biochem. 385, 383-385 (2009)
30. Kabsch, W. Xds. Acta Crystallogr. D 66, 125-132 (2010)
31. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011)
32. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012)
33. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007)
34. Ŝali, A., Potterton, L., Yuan, F., van Vlijmen, H. & Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins, 23. 318-326 (1995).
35. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix. refine. Acta Crystallogr. D 68, 352-367 (2012)
36. Bricogne, G. B. E. et al. BUSTER version 2. 11. 5. (Global Phasing Ltd., 2011)
37. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010)
38. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007)
39. Cer, R. Z., Mudunuri, U., Stephens, R. & Lebeda, F. J. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 37, W441-W445 (2009)
40. Marks, B. D. et al. Multiparameter analysis of a screen for progesterone receptor ligands: comparing fluorescence lifetime and fluorescence polarization measurements. Assay Drug Dev. Technol. 3, 613-622 (2005)
41. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p. p. b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnol. 26, 1367-1372 (2008)